Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajesh Patel

Internal Medicine Lock Haven, PA Medical Doctor

NPI 1013985936 CMS profile 182568

1 Outlet Ln Ste 380, Lock Haven, PA 17745

Open in the dashboard

General payments

$106,993

933 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$145,583 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Rajesh Patel of Lock Haven, PA is reported in the CMS Open Payments database as having received $106,993 across 933 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $145,583 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,578 137
2024 General $17,463 133
2023 General $19,780 151
2022 General $12,509 151
2021 General $15,497 141
2020 General $3,244 84
2019 General $9,921 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajesh Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rajesh Patel were reported at $28,578. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rajesh Patel Internal Medicine median Middle half National median
2019 $9,921 $159 $48–$570 $163
2020 $3,244 $119 $33–$402 $114
2021 $15,497 $135 $37–$521 $132
2022 $12,509 $141 $42–$496 $149
2023 $19,780 $149 $45–$519 $160
2024 $17,463 $154 $47–$537 $164
2025 $28,578 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $27,950 152 payments
  2. AbbVie, Inc. $24,034 82 payments
  3. Phathom Pharmaceuticals, Inc. $18,873 46 payments
  4. Lilly USA, LLC $15,882 127 payments
  5. Janssen Pharmaceuticals, Inc $7,578 80 payments
  6. Eli Lilly and Company $3,080 13 payments
  7. Novo Nordisk AS $1,702 4 payments
  8. Pfizer Inc. $795 48 payments
  9. Amgen Inc. $760 41 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $646 40 payments
  11. Other $5,692 300 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $73,068 46 payments
  2. Food and Beverage $16,795 831 payments
  3. Travel and Lodging $12,794 41 payments
  4. Consulting Fee $4,140 3 payments
  5. Education $196 12 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $23,164 54 payments
  2. RYBELSUS $18,948 96 payments
  3. VOQUEZNA $18,760 36 payments
  4. MOUNJARO $12,229 76 payments
  5. Ozempic $9,703 112 payments
  6. INVOKANA $6,652 30 payments
  7. XARELTO $1,166 68 payments
  8. QULIPTA $700 25 payments
  9. Kerendia $646 40 payments
  10. ELIQUIS $503 32 payments
  11. Other $10,530 585 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 148 drugs

Part D claims

8,592

Median for Internal Medicine: 777

Drug cost

$1,317,805

Median for Internal Medicine: $73,373

Branded share of claims

26.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Korlym Mifepristone Brand 11 $223,362
Xarelto Rivaroxaban Brand 281 $168,628
Eliquis Apixaban Brand 254 $123,147
Jardiance Empagliflozin Brand 154 $112,201
Rybelsus Semaglutide Brand 90 $101,701
Mounjaro Tirzepatide Brand 73 $89,383
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 85 $78,626
Kerendia Finerenone Brand 54 $40,512
Linzess Linaclotide Brand 54 $34,104
Trulicity Dulaglutide Brand 25 $30,874

The 10 drugs with the highest cost, of 148 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$146,733

Of which drugs: $19,190

Medicare patients

203

Average age 76

Services billed

2,674

113 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Depression 41%
Diabetes 38%
Chronic kidney disease 34%
COPD 31%
Ischemic heart disease 30%
Atrial fibrillation 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 35 35 $2,864
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 11 11 $1,439

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$15,524 17 —
QULIPTA
$189 — —
Korlym
$181 11 —
MOUNJARO
$168 73 —
ZENPEP
$141 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

933 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record